News

At-home color shines

BY Antoinette Alexander

Gel manicures are one of the more popular salon services in the professional market, and now beauty mavens can create the look at home — for a fraction of the price — thanks to several new innovations hitting the mass market. As a result, the nail color segment at mass is likely to experience continued growth.


After years of lackluster sales, nail color has, and continues to be, a shining star at mass with sales experiencing double-digit gains. Now, several manufacturers are launching at-home gel polish to further drive sales and bring the salon experience home.


Red Carpet Manicure in September launched nationwide at Ulta its at-home LED gel polish manicure and pedicure system, which offers 36 different shades of gel polish. A full system costs $57.94, or $2.90 each for 20 at-home applications.


Pacific World has developed its new SensatioNail gel polish system, which will hit the mass market as early as November on a promotional basis before rolling out on a larger scale in next year’s planogram. SensatioNail, which also works with an LED light, offers a range of 12 shades of gel polish. A starter kit, offering enough product for 10 manicures, will be priced at $50 to $60.


CCA Industries began shipping in September its new Nutra Nail Gel Perfect UV-free gel color, which is available in 12 shades for $11.99 each, which is about $3 per application.


Another innovative product making major waves in nail color is Sally Hansen’s Salon Effects, which is the No. 1 cosmetics launch in 2011 year to date.


To learn more about what nail trends are being spotted in professional nail salons, check out the new Kiss-sponsored video at DrugStoreNews.com.


 

The article above is part of the DSN Category Review Series. For the complete Nail Care Buy-In Report, including extensive charts, data and more analysis, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Consumer awareness boosts probiotics

BY Michael Johnsen

Probiotics are fast moving from a “what’s that?” category to a “what’s hot” category. Most people today know the health benefits associated with probiotic use — a 2010 MaCorr Research consumer survey reported that 73% of consumers correctly identified probiotic use, up from only 47% in 2007 — and that’s thanks in large part to the educational efforts of Procter & Gamble with its Align launch two years ago, and prior to that, Danone with its Activia yogurt launch.


Now advertising for the category is moving into a product differentiation phase. In addition to P&G — which according to reports has switched gears from educating consumers on probiotic use to promoting specific use of Align — there is Schiff Nutritional, which earlier this year acquired probiotic brands Sustenex and Digestive Advantage.


“The integration [of the probiotic brands] is now complete,” Schiff CEO, president and director Tarang Amin told analysts in September. “In the first quarter, we turned on advertising support and are pursuing further distribution opportunities.” With that acquisition, Schiff will be looking to increase trial across a category already realizing more than 80% annualized growth, according to SymphonyIRI Group data.

 

The article above is part of the DSN Category Review Series. For the complete Digestives Buy-In Report, including extensive charts, data and more analysis, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Antacids expect some upset

BY Michael Johnsen

Sales of antacid tablets are up almost 3%. And while nobody is suggesting that upward trajectory is going to change anytime soon, there will be a decent amount of volatility in the coming year.


Proton-pump inhibitors Prevacid 24HR and Zegerid OTC now have been on the shelf for a little more than a year, and those products appear to have generated accretive sales to the category, as opposed to stealing share from their competitors. In fact, only two antacid brands realized a decline in sales over the past year — Procter & Gamble’s Prilosec OTC and McNeil Consumer’s Pepcid brand family.


The less-than-4% decline in Prilosec OTC sales is nominal, considering the brand faced down both PPI introductions and continued store-brand erosion, and it still is the No. 1 antacid by a more than $150 million margin. Sales declines across the Pepcid brand are attributed to the number of product recalls McNeil Consumer had to make in the past two years.


The volatility in the category will be generated by McNeil’s Pepcid and GlaxoSmithKline’s Tagamet. McNeil is close to relaunching many of those recalled products — some in late 2011 and the rest in 2012 — and the speculation is the marketing behind that reintroduction will be considerable. And GlaxoSmithKline’s Tagamet HB 200 is one of the brands on the sales block, suggesting any acquiring company will at least breathe some new marketing life into that brand through social media.

 

The article above is part of the DSN Category Review Series. For the complete Digestives Buy-In Report, including extensive charts, data and more analysis, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES